How LC-MS/MS will help you overcome your challenges in TDM
Join Waters online TDM Webinar on March 15 to hear about LC-MS based applications and learnings to improve your day-to-day results. A specific focus on novel Antibiotics and Immunosuppressants methods will highlight multiplexing, throughput, ease of use and robustness.
What you will learn during this session:
- The breadth of existing LC/MS-MS based applications
- How to improve your day-to-day results
- A specific focus on novel Antibiotics and Immunosuppressants methods
- Advantages of multiplexing leading to increased throughput with ease of use and robustness.
What is TDM?
The International Association for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) adopted the following definition:
“TDM is a multi-disciplinary clinical specialty aimed at improving patient care by individually adjusting the dose of drugs for which clinical experience or clinical trials have shown it improved outcome in the general or special populations. It can be based on a a priori pharmacogenetic, demographic and clinical information, and/or on the a posteriori measurement of blood concentrations of drugs (pharmacokinetic monitoring) and/or biomarkers (pharmacodynamic monitoring).”
Presenter: Stephen Balloch (Senior Scientist, Clinical Scientific Operations, Waters Corporation)
Stephen Balloch graduated from the University of York (UK) with a Masters degree in Chemistry which included a strong focus on analytical chemistry and a year in industry, in which he gained experience in a range of analytical techniques.
His first permanent post was at Charles River Laboratories, a GLP compliant contract research laboratory in Edinburgh, in which he progressed to the role of Study Director and gained further exposure to LC-MS and LC-MS/MS instrumentation, including Waters instruments.
Since 2010, he has been part of the clinical team in the Scientific Operations group in Waters (Wilmslow, UK). His principal focus has been on the development and validation of bioanalytical methods according to CLSI guidelines, with a focus on therapeutic drug monitoring. Additionally, he has supported newborn screening, steroid and vitamin analysis.
